The prolactin antagonist-ES fusion protein is a bifunctional protein, which inhibits both breast cancer cell proliferation and endothelial cell proliferation, exhibiting greater tumor inhibitory effects than prolactin antagonist and ES treated individually or in combination [29]. The gene discussed is PRL; the disease is breast cancer.